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Since the original description of glial neoplasms 
consisting of cells with oligodendroglial morphol- 
ogy [1] many papers have addressed the clinical be- 
havior of this tumor. While their name was derived 
from a characteristic appearance in silver stains as 
tumors composed of glial cells with few and short 
processes, the hallmark of oligodendrogliomas  
shown in hematoxylin and eosin stains became the 
typical honeycomb structure. Soon after its recog- 
nition it became clear that in a considerable number 
of oligodendrogliomas trocytic cells were en- 
countered, and after the introduction of immuno- 
histochemical stains for glial fibrillary acidic pro- 
tein, a marker for the astrocytic ell lineage, even 
more oligodendroglial neoplasms appeared to har- 
bor astrocytic cells [2, 3]. Only a limited number of 
recent studies pecifically addresses the problem of 
how to distinguish oligodendrogliomas from the 
mixed oligo-astrocytomas by mentioning maximum 
allowable percentages of astrocytic ells [6-9]. In 
recent years immunohistochemical m rkers pecifi- 
cally reacting with the cells of oligodendrogliomas 
have been sought but not yet found [4, 5]. 
Besides the well known difficulties in predicting 
clinical outcome of neoplasms based on histopath- 
ology, as interference of other prognostically rele- 
vant parameters, and besides the limited represen- 
tation of a small biopsy sample from tumors as het- 
erogenous as gliomas [10], clinicopathological in- 
vestigations were hampered by the relatively 
rareness of this member of the glioma family. Fur- 
thermore, there is no consensus regarding the legiti- 
mation of individual histopathological features 
used in grading schemes for oligodendrogliomas. In 
several recent studies grading schemes consisting of 
various features have been tested with regard to 
their predictive power [6, 7, 9, 11, 12]. No major dif- 
ferences were apparent between the survival curves 
resulting from application of the original, rather ill- 
defined scheme of Kernohan, and those obtained 
by using the schemes later developed by the AFIR 
or that used by a french-american group (St. Anne- 
Mayo) [9, 12]. 
Some studies were aimed at identifying individu- 
al histopathological features with significance for 
prognosis. The results of these studies do not pro- 
vide a consensus. In a large Norwegian study the 
features cell density, necrosis and microcysts were 
found to have prognostic significance [7]. In con- 
trast, in the largest study on oligodendrogliomas to 
date so far, viz. the AFIP series, only nuclear pleo- 
morphism was identified as individual significant 
factor [6]. Stepwise regression analysis used in an- 
other American study revealed that necrosis and 
the number of mitoses contained all prognostically 
usefull information. The St. Anne-Mayo scheme, 
not exclusively used for oligodendrogliomas, but 
successfully applied to astrocytomas  well [13], 
promised to become a good scheme in grading oli- 
godendrogliomas because of encompassing fea- 
tures of undebatable significance [12]. In addition to 
cell density, nuclear pleomorphism, endothelial b- 
normality and necrosis, the feature of mitotic index, 
proven to be a significant parameter, is used in this 
scheme as well [9, 11]. However, application on a 
group of cases of the Mayo Clinic yielded no more 
30 
than two (and not three) distinct survival curves 
[12]. 
Immunohistochemical analysis of proliferation 
using anti-Ki-67 antibody including that developed 
for formalin-fixed, paraffin-embedded tissue 
Mib-1, yielded good correlations with tumor grade 
and clinical outcome [14]. Ploidy patterns obtained 
by DNA-flow cytometry on oligodendroglial tu- 
mors were not correlated with histopathological 
features, nor indicative for biological behavior [15]. 
However, S-phase fraction roughly correlated with 
tumor grade [10]. 
The role of age in clinical outcome of patients uf- 
fering from oligodendrogliomas has been a matter 
of controversy. In the large study by MCrk patient's 
age seemed not to influence survival [7]. On the 
contrary, age was found to be an important prog- 
nostic factor correlating with tumor grade in several 
other studies [3, 6,11,12,16]. In our own material we 
found that younger patients urvive longer. How- 
ever, confounding factors in age effects on survival 
are correlations of younger age with lower histo- 
pathological grade and with more favorable (i.e., 
frontal) localizations of the oligodendrogliomas 
[16]. 
While inconclusive and contradictory statements 
concerning the influence of tumor localization were 
made in the earliest reports on oligodendrogliomas 
[17-19], only few recent studies focussed attention 
on tumor site [12,16]. In 1950 Earnest and Kernohan 
wrote that tumor site, i.e., frontal versus non-frontal 
(hemispheric) localization, would provide all prog- 
nostic information, and that even grading the tu- 
mors in a two-tiered scheme (viz. oligodendroglio- 
mas and olig0dendroblastomas ) would be redun- 
dant [19]. While the beneficial effect of frontal tu- 
mor site on survival could be confirmed indeed, the 
supposed irrelevance of grading was falsified by 
succesfully grading in the group of frontal ocalized 
neoplasms [16]. 
Satisfactory volumetric measurements, compat- 
ible with histopathologic tumor borders, can be ob- 
tained from CT scans. Estimations of tumor growth 
rate based on increase in tumor volume measured 
from subsequential CT scans, however, are limited 
to cases with relatively substantial changes in tumor 
bulk. In those 43 cases from our series in which CT 
scans were available, no correlation between tumor 
size and survival, nor between tumor size and histo- 
pathological grade, was found [16]. The results were 
not different for those patients who had undergone 
a stereotactic biopsy with assumed minimal remov- 
al of tumor tissue [16]. Tumor recurrence is sup- 
posed to be highly dependent on the residual tumor 
volume after surgery. The reliability of estimations 
of debulked tumor volume is questionable and in 
only one paper linked with survival [12]. Papers ad- 
dressing the relation between volume of rest tumor 
and recurrence are missing because in many centers 
post-operative scans are not routinely made, and 
delineation of true tumor tissue from reactive 
changes based on CT images is difficult, if not im- 
possible. 
The effects of radiation therapy on oligodendro- 
gliomas is still controversial, since all studies eval- 
uating radiotherapy were done retrospectively 
without controlling for variables in patients or the 
tumors [12,16, 20, 21-24]. Analogous with the pros- 
pective, randomized trials in which it was found that 
high grade oligodendrogliomas in particular are re- 
sponsive to chemotherapy [25, 26], trials for the ef- 
fects of radiation therapy should be developed. 
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